PortfoliosLab logoPortfoliosLab logo
NBIX vs. DHR
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NBIX vs. DHR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Neurocrine Biosciences, Inc. (NBIX) and Danaher Corporation (DHR). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NBIX achieves a 16.41% return, which is significantly higher than DHR's -22.04% return. Over the past 10 years, NBIX has outperformed DHR with an annualized return of 12.80%, while DHR has yielded a comparatively lower 10.97% annualized return.


NBIX

1D
6.63%
1M
23.15%
YTD
16.41%
6M
8.65%
1Y
32.09%
3Y*
21.38%
5Y*
11.83%
10Y*
12.80%

DHR

1D
1.12%
1M
2.32%
YTD
-22.04%
6M
-21.78%
1Y
-6.64%
3Y*
-4.53%
5Y*
-3.23%
10Y*
10.97%
*Multi-year figures are annualized to reflect compound growth (CAGR)

NBIX vs. DHR - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
NBIX
Neurocrine Biosciences, Inc.
16.41%3.90%3.60%10.31%40.24%-11.14%-10.83%50.53%-7.96%100.49%
DHR
Danaher Corporation
-22.04%0.35%-0.35%-1.22%-19.02%48.57%45.34%49.55%11.80%20.01%

Correlation

The correlation between NBIX and DHR is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.19

Correlation (3Y)
Calculated over the trailing 3-year period

0.24

Correlation (5Y)
Calculated over the trailing 5-year period

0.24

Correlation (10Y)
Calculated over the trailing 10-year period

0.28

Correlation (All Time)
Calculated using the full available price history since May 24, 1996

0.29

Fundamentals

Market Cap

NBIX:

$17.07B

DHR:

$126.65B

EPS

NBIX:

$6.53

DHR:

$5.17

PE Ratio

NBIX:

25.28

DHR:

34.46

PS Ratio

NBIX:

5.45

DHR:

5.13

PB Ratio

NBIX:

5.01

DHR:

2.39

Total Revenue (TTM)

NBIX:

$3.10B

DHR:

$24.78B

Gross Profit (TTM)

NBIX:

$3.05B

DHR:

$15.04B

EBITDA (TTM)

NBIX:

$881.20M

DHR:

$6.69B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NBIX vs. DHR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NBIX
NBIX Risk / Return Rank: 6868
Overall Rank
NBIX Sharpe Ratio Rank: 7272
Sharpe Ratio Rank
NBIX Sortino Ratio Rank: 6666
Sortino Ratio Rank
NBIX Omega Ratio Rank: 6767
Omega Ratio Rank
NBIX Calmar Ratio Rank: 6969
Calmar Ratio Rank
NBIX Martin Ratio Rank: 6868
Martin Ratio Rank

DHR
DHR Risk / Return Rank: 3030
Overall Rank
DHR Sharpe Ratio Rank: 3030
Sharpe Ratio Rank
DHR Sortino Ratio Rank: 2626
Sortino Ratio Rank
DHR Omega Ratio Rank: 2727
Omega Ratio Rank
DHR Calmar Ratio Rank: 3333
Calmar Ratio Rank
DHR Martin Ratio Rank: 3131
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NBIX vs. DHR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and Danaher Corporation (DHR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


NBIXDHRDifference
Sharpe ratioReturn per unit of total volatility

+1.28

Sortino ratioReturn per unit of downside risk

+1.71

Omega ratioGain probability vs. loss probability

1.21

0.98

+0.23

Calmar ratioReturn relative to maximum drawdown

1.54

-0.20

+1.74

Martin ratioReturn relative to average drawdown

3.39

-0.50

+3.89

NBIX vs. DHR - Sharpe Ratio Comparison

The current NBIX Sharpe Ratio is 1.04, which is higher than the DHR Sharpe Ratio of -0.24. The chart below compares the historical Sharpe Ratios of NBIX and DHR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


NBIXDHRDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.04

-0.24

+1.28

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.36

-0.12

+0.48

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.33

0.43

-0.10

Sharpe Ratio (All Time)

Calculated using the full available price history

0.15

0.64

-0.50

Drawdowns

NBIX vs. DHR - Drawdown Comparison

The maximum NBIX drawdown since its inception was -97.21%, which is greater than DHR's maximum drawdown of -45.80%. Use the drawdown chart below to compare losses from any high point for NBIX and DHR.


Loading charts...

Drawdown Indicators


NBIXDHRDifference

Max Drawdown

Largest peak-to-trough decline

-97.21%

-45.80%

-51.41%

Max Drawdown (1Y)

Largest decline over 1 year

-20.90%

-32.97%

+12.07%

Max Drawdown (3Y)

Largest decline over 3 years

-42.89%

-41.72%

-1.17%

Max Drawdown (5Y)

Largest decline over 5 years

-42.89%

-43.81%

+0.92%

Max Drawdown (10Y)

Largest decline over 10 years

-46.39%

-43.81%

-2.58%

Current Drawdown

Current decline from peak

0.00%

-38.20%

+38.20%

Average Drawdown

Average peak-to-trough decline

-43.85%

-10.21%

-33.64%

Ulcer Index

Depth and duration of drawdowns from previous peaks

9.48%

13.26%

-3.78%

Volatility

NBIX vs. DHR - Volatility Comparison

Neurocrine Biosciences, Inc. (NBIX) has a higher volatility of 12.60% compared to Danaher Corporation (DHR) at 7.84%. This indicates that NBIX's price experiences larger fluctuations and is considered to be riskier than DHR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NBIXDHRDifference

Volatility (1M)

Calculated over the trailing 1-month period

12.60%

7.84%

+4.76%

Volatility (6M)

Calculated over the trailing 6-month period

23.57%

18.84%

+4.73%

Volatility (1Y)

Calculated over the trailing 1-year period

31.08%

27.70%

+3.38%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

32.72%

27.92%

+4.80%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

39.19%

25.48%

+13.71%

Dividends

NBIX vs. DHR - Dividend Comparison

NBIX has not paid dividends to shareholders, while DHR's dividend yield for the trailing twelve months is around 0.76%.


PositionTTM20252024202320222021202020192018201720162015
DHR
Danaher Corporation
0.76%0.56%0.47%12.64%0.38%0.26%0.32%0.44%0.62%0.60%32.55%0.58%
NBIX
Neurocrine Biosciences, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

NBIX vs. DHR - Financials Comparison

This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and Danaher Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00B4.00B6.00B8.00B20222023202420252026
814.50M
5.95B
(NBIX) Total Revenue
(DHR) Total Revenue
Values in USD except per share items

NBIX vs. DHR - Profitability Comparison

The chart below illustrates the profitability comparison between Neurocrine Biosciences, Inc. and Danaher Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

60.0%70.0%80.0%90.0%100.0%20222023202420252026
98.3%
60.3%
Portfolio components
NBIX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a gross profit of 800.70M and revenue of 814.50M. Therefore, the gross margin over that period was 98.3%.

DHR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Danaher Corporation reported a gross profit of 3.59B and revenue of 5.95B. Therefore, the gross margin over that period was 60.3%.

NBIX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported an operating income of 193.40M and revenue of 814.50M, resulting in an operating margin of 23.7%.

DHR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Danaher Corporation reported an operating income of 1.34B and revenue of 5.95B, resulting in an operating margin of 22.6%.

NBIX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a net income of 197.90M and revenue of 814.50M, resulting in a net margin of 24.3%.

DHR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Danaher Corporation reported a net income of 1.03B and revenue of 5.95B, resulting in a net margin of 17.3%.


Frequently Asked Questions


NBIX and DHR have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NBIX has higher volatility (12.60%) compared to DHR (7.84%). In terms of maximum drawdown, NBIX dropped -97.21% vs DHR's -45.80%.

NBIX currently has the higher Sharpe Ratio (1.04 vs -0.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NBIX and DHR

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer